The reliability and validity of the Greek version of the Pediatric Quality of Life Inventory™ 3.0 Duchenne muscular dystrophy module in children with Duchenne muscular dystrophy
, 1, 3, 4
Abstract
Introduction: This cross-sectional study aimed to evaluate the reliability and validity of the Greek version of the Pediatric Quality of Life Inventory™ (PedsQL™) 3.0 Duchenne muscular dystrophy (DMD) module.
Methods: The Greek version of PedsQL™ 3.0 DMD was completed by children with DMD and their parents/caregivers during their annual clinical visit to a hospital setting. Internal consistency reliability (Cronbach’s α) and reproducibility (ICC, intraclass correlation coefficients) of the DMD module were assessed, and test-retest reproducibility was evaluated after 6 to 8 months. Known-group validity was evaluated by comparing scores between different patient groups.
Results: A total of 79 children with DMD and their parents/caregivers were enrolled in the study. Internal consistency reliability was confirmed as Cronbach’s α was > 0.70 (total score: child α = 0.8, parent/ /caregiver α = 0.89) and the ICC exceeded 0.6 (for the total score of the child report 0.92 and 0.81 for the parent/caregiver report). Construct validity of PedsQL™ 3.0 DMD module was confirmed. The mean quality of life total score for child self-report was 76.29 ± 13.27 among the ambulatory patients and 56.91 ± 13.27 among the non-ambulatory patients (p < 0.001). The mean quality of life score for the parent/caregiver proxy report was 70.64 ± 20.75 among ambulatory patients and 52.15 ± 22.54 among non-ambulatory patients (p < 0.001). The child self-reports were in good agreement with the parent/ /caregiver proxy reports for most subscales (ICC range 0.49–0.81, 0.57–0.91).
Conclusions: The PedsQL™ 3.0 DMD module is valid and reliable in Greek patients with DMD for measuring disease-specific health-related quality of life (HRQoL).
Keywords: health-related quality of lifeDuchenne muscular dystrophyPedsQLGreek languagepsychometric properties
References
- Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017; 12(1): 79.
- Crisafulli S, Sultana J, Fontana A, et al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020; 15(1): 141.
- Thongsing A, Likasitwattanakul S, Sanmaneechai O. Reliability and validity of the Thai version of the Pediatric Quality of Life inventory™ 3.0 Duchenne Muscular Dystrophy module in Thai children with Duchenne Muscular Dystrophy. Health Qual Life Outcomes. 2019; 17(1): 76.
- Messina S, Vita GL, Sframeli M, et al. Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscul Disord. 2016; 26(3): 189–196.
- Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018; 17(3): 251–267.
- Larkindale J, Yang W, Hogan PF, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014; 49(3): 431–438.
- Cavazza M, Kodra Y, Armeni P, et al. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Eur J Health Econ. 2016; 17 Suppl 1: 19–29.
- Teoh LJ, Geelhoed EA, Bayley K, et al. Health care utilization and costs for children and adults with duchenne muscular dystrophy. Muscle Nerve. 2016; 53(6): 877–884.
- Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with duchenne muscular dystrophy in the united states. J Manag Care Spec Pharm. 2017; 23(6): 633–641.
- Schreiber-Katz O, Klug C, Thiele S, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014; 9: 210.
- Medicines Agency E. Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy 2015. https://www.tga.gov.au/sites/default/files/2024-05/EMACHMP2369812011corr1%20GL%20on%20Duchenne%20Becker%20muscular%20dystCurrent%20CURRENT.PDF (31.08.2024).
- European Medicines Agency; Committee for medicinal products for human use (chmp) guideline on clinical trials in small populations draft agreed by efficacy working party / ad hoc group on clinical trials in small populations adoption by chmp for release for consultation. 2002. https://www.tga.gov.au/sites/default/files/2024-06/guideline-clinical-trials-small-populations-ema.pdf (31.08.2024).
- Fda, Cder, Mccrayk. Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry. 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-treatment-guidance (31.08.2024).
- Whittal A, Meregaglia M, Nicod E. The use of patient-reported outcome measures in rare diseases and implications for health technology assessment. Patient. 2021; 14(5): 485–503.
- Gkoltsiou K, Dimitrakaki C, Tzavara C, et al. Measuring health-related quality of life in Greek children: psychometric properties of the Greek version of the Pediatric Quality of Life Inventory(TM) 4.0 Generic Core Scales. Qual Life Res. 2008; 17(2): 299–305.
- Gkoltsiou K, Papaevangelou V, Konstandopoulos A. et al. Children and pilot testing of the Greek Version of the PedsQL 4.0 Instrument. Youth. Peer-reviewed Section. PRO Newsletter 2006; 37. https://www.gkoltsiou.gr/system/assets/000/000/078/original_Pilot_Testing_of_the_Greek_Version_of_the.pdf?1303307155 (31.08.2024).
- Katsomiti E, Kastanioti C, Chroni E, et al. Pediatric quality of life inventory (pedsql) 3.0 duchenne muscular dystrophy module-Greek translation: a quality of life tool in duchenne muscular dystrophy. WSEAS Transact Biol Biomed. 2023; 20: 267–274.
- Tang P, Lu Q, Wu Y, et al. The Chinese version of the Quality of Life in Childhood Epilepsy Questionnaire-16-C (QOLCE-16-C): translation, validity, and reliability. Health Qual Life Outcomes. 2022; 20(1): 52.
- Varni JW, Limbers CA, Burwinkle TM. Parent proxy-report of their children's health-related quality of life: an analysis of 13,878 parents' reliability and validity across age subgroups using the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007; 5: 2.
- Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951; 16: 297–334.
- Steffen TM, Hacker TA, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds. Phys Ther. 2002; 82(2): 128–137.
- Weir JP. Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res. 2005; 19(1): 231–240.
- Hu J, Jiang Li, Hong S, et al. Reliability and validity of the Chinese version of the Pediatric Quality Of Life InventoryTM (PedsQLTM) 3.0 neuromuscular module in children with Duchenne muscular dystrophy. Health Qual Life Outcomes. 2013; 11: 47.
- Uzark K, King E, Cripe L, et al. Health-related quality of life in children and adolescents with Duchenne muscular dystrophy. Pediatrics. 2012; 130(6): e1559–e1566.
- Otto C, Steffensen BF, Højberg AL, et al. Predictors of health-related quality of life in boys with duchenne muscular dystrophy from six european countries. J Neurol. 2017; 264(4): 709–723.
- Wei Yi, Speechley KN, Zou G, et al. Factors associated with health-related quality of life in children with Duchenne muscular dystrophy. J Child Neurol. 2016; 31(7): 879–886.
